Comparison · NCT02730377-deaths
Liraglutide 1.8 mg vs Oral Antidiabetic Drug: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liraglutide 1.8 mg vs Oral Antidiabetic Drug: deaths from any cause. Trial comparisons, record NCT02730377-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02730377-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00102 | 0.00018 | 0.00576 | wilson | |
| Risk in group 2 | 0.00813 | 0.00413 | 0.016 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00711 | -0.015 | -0.000907 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.126 | 0.0157 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.125 | 0.0156 | 0.998 | log | |
| Number needed to treat, for one fewer death from any cause on Liraglutide 1.8 mg than on Oral Antidiabetic Drug | 141 | 66.7 | 1,100 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liraglutide 1.8 mg | Participants were to receive a subcutaneous injection of liraglutide once daily. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the dose of 1.8 mg was reached. The treatment period was 104 weeks. | 1 | 980 | EG000 |
| Group 2 | Oral Antidiabetic Drug | Participants were to receive one selected OAD. The following OADs were allowed: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, sulfonylureas or thiazolidinediones. The treatment period was 104 weeks. | 8 | 984 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Weeks 0-105
Source ClinicalTrials.gov
Trial
- Title
- Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
- NCT number
- NCT02730377
- Phases
- PHASE4
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
- Lead sponsor
- Novo Nordisk A/S
- Results first posted
- 2020-07-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02730377?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02730377-deaths